Travere Therapeutics, Inc. (TVTX) is a Biotechnology company in the Healthcare sector, currently trading at $42.13. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of TVTX = $292.29 (+593.8% from the current price, the stock appears undervalued). Analyst consensus target is TVTX = $49 (+16.3% upside).
Valuation: TVTX trades at a trailing Price-to-Earnings (P/E) of -54.3 (S&P 500 average ~25).
Financials: revenue is $491M, +46.5%/yr average growth. Net income is $50M (loss), growing at -14.8%/yr. Net profit margin is -10.2% (negative). Gross margin is 85.5% (-10.9 pp trend).
Balance sheet: total debt is $329M against $115M equity (Debt-to-Equity (D/E) ratio 2.86, leveraged). Current ratio is 2.74 (strong liquidity). Debt-to-assets is 54.3%. Total assets: $605M.
Analyst outlook: 15 / 18 analysts rate TVTX as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 55/100 (Partial), Future 88/100 (Pass), Income 10/100 (Fail).
